.
El síndrome metabólico (SM) es una entidad compuesta por diversas alteraciones que confieren un aumento del riesgo cardiovascular y de diabetes a largo plazo. Sus características en pacientes con síndromes coronarios agudos (SCA) son prácticamente desconocidas. ObjetivosDeterminar la prevalencia, las características y el valor pronóstico del síndrome metabólico (SM) en los síndromes coronarios agudos (SCA). Evaluar su correlación con los factores de riesgo coronario (FRC) y los hábitos dietéticos y analizar una nueva definición recientemente propuesta. Material y métodosSe incluyeron pacientes consecutivos ingresados en Unidad Coronaria con infarto agudo de miocardio o angina inestable. Se diagnosticó SM en base a los criterios del NCEP-ATP III. La nueva definición analizada fue la propuesta por la International Diabetes Federation. ResultadosSe incluyeron en el estudio 239 pacientes. El SM estuvo presente en el 53,3 % de los casos y fue más frecuente en las mujeres (OR 2,53; IC 95%: 1,24-5,18) (p = 0,005). No presentó correlación significativa con el pronóstico hospitalario ni con los hábitos dietéticos. Su prevalencia según la nueva definición fue casi idéntica (53%) y si bien tuvo valor pronóstico en el análisis univariado, no lo conservó en el multivariado. ConclusionesLa prevalencia del SM en los SCA es más elevada que la informada para otras poblaciones. No parece tener valor pronóstico a corto plazo. La nueva definición no modificó su prevalencia ni agregó información pronóstica independiente.
Placenta accreta spectrum (PAS) is a life-threatening obstetric condition associated with increasing cesarean delivery rates worldwide. Existing classifications, such as the World Health Organization International Statistical Classification of Diseases and Health-Related Problems and the International Federation of Gynecology and Obstetrics system, describe depth of invasion and histopathological features but do not adequately predict surgical outcomes or guide individualized management. The PAS topographic classification describes the anatomical extent of uterine wall remodeling and the presence of uterovesical adhesions, allowing surgical teams to anticipate intraoperative complexity, organ involvement, and appropriate therapeutic strategies. Although successfully applied in selected centers, its broader evaluation across diverse healthcare settings is lacking. We designed a prospective, multicenter, international cohort study enrolling patients with a high prenatal suspicion of PAS. Eligible patients are aged ≥ 18 years, undergoing surgery after 20 weeks’ gestation, and managed by multidisciplinary PAS teams familiar with the topographic classification. Standardized prenatal ultrasound staging and intraoperative surgical staging are required, with photographic and video documentation. Surgical strategies include one-step conservative surgery, total hysterectomy, and modified subtotal hysterectomy, guided by intraoperative classification. The primary outcome is intraoperative blood loss, measured using a standardized protocol. Secondary outcomes include intraoperative complications, operative time, treatment type, and usability assessments of the classification through structured surveys. Data are collected in REDCap with external review of imaging records. This study will provide the first prospective, multicenter evaluation of the PAS topographic classification, assessing its correlation with clinical outcomes and its feasibility across hospitals with varying resources and surgical expertise. Preliminary results indicate successful implementation in both high- and low-volume centers, with promising adoption of prenatal ultrasound staging and surgical protocols. The collaborative, image-based, and open-access methodology aims to strengthen the reliability of PAS research by harmonizing surgical strategies and allowing external supervision. Ultimately, this project will generate robust multicenter data to inform individualized management strategies and support the integration of the topographic classification into routine clinical practice worldwide. ClinicalTrials.gov Identifier: NCT05922397. Registered on 21 May 2023.
El presente trabajo destaca la relevancia de la investigación en pediatría, así como los retos y dilemas éticos asociados a la obtención del asentimiento o consentimiento libre e informado. Se analiza la normativa argentina aplicable en este ámbito y se propone un modelo de implementación que puede adoptarse como referencia práctica para investigadores y comités de ética en investigación.
ObjectivesTo compare the treatments used for the first episode of lupus nephritis (LN) in two Latin American cohorts (historical and contemporary) over a 25-year period, and their associations with clinical outcomes.MethodsPatients with biopsy-confirmed first LN episode were classified as non-proliferative (class V) or proliferative (classes III/IV). Sociodemographic, clinical, and treatment variables were described. Propensity score matching was used to examine the associations with four outcomes: mortality, damage accrual (SDI), hospitalization, and end-stage renal disease (ESRD).ResultsA total of 532 SLE patients were included: 362 from GLADEL 1.0 (historical cohort) and 170 from GLADEL 2.0. (contemporary). Compared to GLADEL 1.0, patients in GLADEL 2.0 received lower doses of oral glucocorticoids (GC), more frequently GC pulses and antimalarials but less frequently cyclophosphamide. An increase in the use of mycophenolate mofetil and other immunosuppressants was also observed. In the logistic regression models, SDI was associated with baseline SDI and GC pulses, whereas belonging to the GLADEL 2.0 was a protective factor. Mortality was associated with Mestizo ethnicity and partial health coverage; antimalarial was identified as a protective factor. Hospitalizations were associated with baseline SLEDAI and SDI, follow-up time, and lower educational level. Belonging to the GLADEL 2.0 cohort was protective against the occurrence of ESRD.ConclusionsPatients in the contemporary cohort benefited from advances in treatment strategies, with less cumulative damage and progression to ESRD, although mortality remained unchanged. These improvements likely reflect the increased use of newer therapies, more targeted approaches, in line with current treatment guidelines, and better access to specialized care.
